CENPJ: A Potential Drug Target and Biomarker for Centrosomal Protein 4.1-Associated Diseases

Target Name: CENPJ

NCBI ID: G55835

CENPJ

CENPJ: A Potential Drug Target and Biomarker for Centrosomal Protein 4.1-Associated Diseases

Introduction

Centrosomal protein 4.1 (CENPJ) is a protein that is expressed in a variety of tissues and is involved in the proper functioning of the mitotic spindle. CENPJ has been implicated in the development and maintenance of various diseases, including neurodegenerative disorders, cancer, and developmental defects. As a result, CENPJ has emerged as a promising drug target and biomarker for a variety of diseases.

Diseases associated with CENPJ

CENPJ is involved in several critical processes in cell biology, including the proper formation and stability of the mitotic spindle. It is a key component of the microtubules that provide structural support to the spindle and help to ensure the proper separation of sister chromatids during mitosis. CENPJ is also involved in the regulation of the spindle formation and stability, as well as the assembly and disassembly of the spindle.

Neurodegenerative disorders

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells. These disorders are often associated with the misfolding and mislocalization of proteins, including CENPJ. Research has shown that misfolded forms of CENPJ have been identified in neurodegenerative brain tissue and have been shown to contribute to the development and progression of these disorders. Therefore, targeting CENPJ with drugs that can modulate its function may be a promising strategy for the development of new treatments for neurodegenerative disorders.

Cancer

CENPJ is also involved in the regulation of cell division and has been implicated in the development and progression of cancer. In addition, CENPJ has been shown to be involved in the regulation of angiogenesis, a process that is critical for the growth and survival of cancer. cells. Therefore, targeting CENPJ with drugs that can inhibit its function may be a promising strategy for the development of new treatments for cancer.

Developmental defects

CENPJ is also involved in the regulation of cellular processes that are critical for normal development and growth. Disruptions in CENPJ function have been implicated in the development of a variety of developmental defects, including Down syndrome and trisomy 21. These disorders are characterized by the presence of extra or missing chromosomes and can result in the abnormal development and growth of various body systems. Therefore, targeting CENPJ with drugs that can modulate its function may be a promising strategy for the development of new treatments for developmental defects.

Drugs that can target CENPJ

Several drugs that have been shown to target CENPJ and modulate its function have been identified and are currently in use. These drugs include:

1. Kinesin-associated protein 2 (KAP2): KAP2 is a protein that is highly similar to CENPJ and has been shown to interact with CENPJ. Drugs that target KAP2 have been shown to be effective in modulating the function of CENPJ and have been shown to be potential treatments for neurodegenerative disorders.
2. Pyruvate dehydrogenase complex (PDH1): PDH1 is a protein that is involved in the metabolism of pyruvate, a critical fuel for cellular energy production. CENPJ has been shown to interact with PDH1 and has been shown to play a role in the regulation of cellular energy production. Drugs that target PDH1 have been shown to be effective in modulating the function of CENPJ and have been shown to have potential as

Protein Name: Centromere Protein J

Functions: Plays an important role in cell division and centrosome function by participating in centriole duplication (PubMed:17681131, PubMed:20531387). Inhibits microtubule nucleation from the centrosome. Involved in the regulation of slow processive growth of centriolar microtubules. Acts as microtubule plus-end tracking protein that stabilizes centriolar microtubules and inhibits microtubule polymerization and extension from the distal ends of centrioles (PubMed:15047868, PubMed:27219064, PubMed:27306797). Required for centriole elongation and for STIL-mediated centriole amplification (PubMed:22020124). Required for the recruitment of CEP295 to the proximal end of new-born centrioles at the centriolar microtubule wall during early S phase in a PLK4-dependent manner (PubMed:27185865). May be involved in the control of centriolar-microtubule growth by acting as a regulator of tubulin release (PubMed:27306797)

The "CENPJ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CENPJ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets